Environmental Chemistry Letters

, Volume 16, Issue 1, pp 35–41 | Cite as

Therapeutic applications of resveratrol nanoformulations

Review
First Online:
Received:
Accepted:

Abstract

Resveratrol, or 3, 5, 4-trihydroxy-trans-stilbene, is a naturally occurring polyphenol present in several dietary sources such as grapes, soybeans, berries, pomegranate and peanuts. Resveratrol has received recent attention due to its diverse pharmacological activities. However, resveratrol clinical efficacy is limited due to its poor systemic bioavailability, of less than 1%, which is due to its low aqueous solubility, extensive first-pass metabolism and existence of enterohepatic recirculation. Therefore, in order to overcome these limitations, various nanocarriers including polymeric nanoparticles, solid lipid nanoparticles, liposomes, micelles and conjugates have been developed. These nanocarriers are able to enhance the bioavailability of resveratrol by modulating the P-glycoprotein, cytochrome P-450 enzymes and bypassing the hepatic first-pass effect. Here we review resveratrol nanoformulations for enhancing the efficacy of native resveratrol.

Keywords

Resveratrol Bioavailability Nanoformulation Targeting Anticancer 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgements

SJ thankfully acknowledge the SERB, DST Govt. of India for Grant No. ECR/2017/001381. DA thankfully acknowledges the support in the form of research fellowships by Council of Scientific and Industrial Research (CSIR), New Delhi. The manuscript bears institutional communication No. IIIM/2151/2017.

References

  1. Akbarzadeh A et al (2013) Liposome: classification, preparation, and applications. Nanoscale Res Lett 8(1):1. doi: 10.1186/1556-276X-8-102 CrossRefGoogle Scholar
  2. Al-Achi A, Lawrence J (2013) Micelles: chemotherapeutic drug delivery. Clin Pharmacol Biopharm 2:e114. doi: 10.4172/2167-065X.1000e114 CrossRefGoogle Scholar
  3. Albuquerque RV et al (2015) In vitro protective effect and antioxidant mechanism of resveratrol induced by dapsone hydroxylamine in human cells. PLoS ONE 10(8):e0134768. doi: 10.1371/journal.pone.0134768 CrossRefGoogle Scholar
  4. Allen TM (1997) Liposomes. Opportunities in drug delivery. Drugs 54(Suppl 4):8–14. doi: 10.2165/00003495-199700544-00004 CrossRefGoogle Scholar
  5. Almeida L et al (2009) Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol Nutr Food Res 53(S1):S7–S15. doi: 10.1002/mnfr.200800177 CrossRefGoogle Scholar
  6. Arora D, Jaglan S (2016) Nanocarriers based delivery of nutraceuticals for cancer prevention and treatment: a review of recent research developments. Trends Food Sci Technol 54:114–126. doi: 10.1016/j.tifs.2016.06.003 CrossRefGoogle Scholar
  7. Arora D, Jaglan S (2017) Nanocarriers for resveratrol delivery. In: Ranjan S, Dasgupta N, Lichtfouse E (eds) Nanoscience in food and agriculture 5, sustainable agriculture reviews, vol 5. Springer, Cham, pp 123–138. doi: 10.1007/978-3-319-58496-6_5 Google Scholar
  8. Bu L et al (2013) Trans-resveratrol loaded chitosan nanoparticles modified with biotin and avidin to target hepatic carcinoma. Int J Pharm 452(1):355–362. doi: 10.1016/j.ijpharm.2013.05.007 CrossRefGoogle Scholar
  9. Buhrmann C, Shayan P, Popper B, Goel A, Shakibaei M (2016) Sirt1 is required for resveratrol-mediated chemopreventive effects in colorectal cancer cells. Nutrients 8(3):145. doi: 10.3390/nu8030145 CrossRefGoogle Scholar
  10. Carletto B et al (2016) Resveratrol-loaded nanocapsules inhibit murine melanoma tumor growth. Colloids Surf B Biointerfaces 144:65–72. doi: 10.1016/j.colsurfb.2016.04.001 CrossRefGoogle Scholar
  11. Carlson LJ, Cote B, Alani AW, Rao DA (2014) Polymeric micellar co-delivery of resveratrol and curcumin to mitigate in vitro doxorubicin-induced cardiotoxicity. J Pharm Sci 103(8):2315–2322. doi: 10.1002/jps.24042 CrossRefGoogle Scholar
  12. Chen Y, Zhang H, Yang J, Sun H (2015) Improved antioxidant capacity of optimization of a self-microemulsifying drug delivery system for resveratrol. Molecules 20(12):21167–21177. doi: 10.3390/molecules201219750 CrossRefGoogle Scholar
  13. Cheserek MJ et al (2016) Cardioprotective effects of lipoic acid, quercetin and resveratrol on oxidative stress related to thyroid hormone alterations in long-term obesity. J Nutr Biochem 33:36–44. doi: 10.1016/j.jnutbio.2016.02.008 CrossRefGoogle Scholar
  14. Coradini K et al (2015) A novel approach to arthritis treatment based on resveratrol and curcumin co-encapsulated in lipid-core nanocapsules: in vivo studies. Eur J Pharm Sci 78:163–170. doi: 10.1016/j.ejps.2015.07.012 CrossRefGoogle Scholar
  15. Cosco D et al (2015) Ultradeformable liposomes as multidrug carrier of resveratrol and 5-fluorouracil for their topical delivery. Int J Pharm 489(1):1–10. doi: 10.1016/j.ijpharm.2015.04.056 CrossRefGoogle Scholar
  16. Criqui MH, Ringel BL (1994) Does diet or alcohol explain the French paradox? Lancet 344(8939):1719–1723. doi: 10.1016/S0140-6736(94)92883-5 CrossRefGoogle Scholar
  17. da Rocha Lindner G et al (2015) Improved neuroprotective effects of resveratrol-loaded polysorbate 80-coated poly (lactide) nanoparticles in MPTP-induced Parkinsonism. Nanomedicine 10(7):1127–1138. doi: 10.2217/nnm.14.165 CrossRefGoogle Scholar
  18. Gescher AJ, Steward WP (2003) Relationship between mechanisms, bioavailibility, and preclinical chemopreventive efficacy of resveratrol: a conundrum. Cancer Epidemiol Biomark Prev 12(10):953–957Google Scholar
  19. Jung K-H et al (2015) Resveratrol-loaded polymeric nanoparticles suppress glucose metabolism and tumor growth in vitro and in vivo. Int J Pharm 478(1):251–257. doi: 10.1016/j.ijpharm.2014.11.049 CrossRefGoogle Scholar
  20. Kaldas MI, Walle UK, Walle T (2003) Resveratrol transport and metabolism by human intestinal Caco-2 cells. J Pharm Pharmacol 55(3):307–312. doi: 10.1211/002235702612 CrossRefGoogle Scholar
  21. Karthikeyan S, Prasad NR, Ganamani A, Balamurugan E (2013) Anticancer activity of resveratrol-loaded gelatin nanoparticles on NCI-H460 non-small cell lung cancer cells. Biomed Prev Nutr 3(1):64–73. doi: 10.1016/j.bionut.2012.10.009 CrossRefGoogle Scholar
  22. Karthikeyan S, Hoti SL, Prasad NR (2015) Resveratrol loaded gelatin nanoparticles synergistically inhibits cell cycle progression and constitutive NF-kappaB activation, and induces apoptosis in non-small cell lung cancer cells. Biomed Pharmacother 70:274–282. doi: 10.1016/j.biopha.2015.02.006 CrossRefGoogle Scholar
  23. Langcake P, Pryce R (1976) The production of resveratrol by Vitis vinifera and other members of the Vitaceae as a response to infection or injury. Physiol Plant Pathol 9(1):77–86. doi: 10.1016/0048-4059(76)90077-1 CrossRefGoogle Scholar
  24. Lavu S, Boss O, Elliott PJ, Lambert PD (2008) Sirtuins—novel therapeutic targets to treat age-associated diseases. Nat Rev Drug Discov 7(10):841–853. doi: 10.1038/nrd2665 CrossRefGoogle Scholar
  25. Liu F-C, Tsai Y-F, Tsai H-I, Yu H-P (2015) Anti-inflammatory and organ-protective effects of resveratrol in trauma-hemorrhagic injury. Mediat Inflamm 2015:643763. doi: 10.1155/2015/643763 Google Scholar
  26. Lu L-Y et al (2015) Pomegranate seed oil exerts synergistic effects with trans-resveratrol in a self-nanoemulsifying drug delivery system. Biol Pharm Bull 38(10):1658–1662. doi: 10.1248/bpb.b15-00371 CrossRefGoogle Scholar
  27. Marier J-F, Vachon P, Gritsas A, Zhang J, Moreau J-P, Ducharme MP (2002) Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. J Pharmacol Exp Therap 302(1):369–373. doi: 10.1124/jpet.102.033340 CrossRefGoogle Scholar
  28. Mason TG, Wilking J, Meleson K, Chang C, Graves S (2006) Nanoemulsions: formation, structure, and physical properties. J Phys: Condens Matter 18(41):R635. doi: 10.1088/0953-8984/18/41/R01 Google Scholar
  29. Mattarei A et al (2013) Acetal derivatives as prodrugs of resveratrol. Mol Pharm 10(7):2781–2792. doi: 10.1021/mp400226p CrossRefGoogle Scholar
  30. Meng J, Guo F, Xu H, Liang W, Wang C, Yang XD (2016) Combination therapy using co-encapsulated resveratrol and paclitaxel in liposomes for drug resistance reversal in breast cancer cells in vivo. Sci Rep 6:22390. doi: 10.1038/srep22390 CrossRefGoogle Scholar
  31. Montsko G et al (2008) Determination of products derived from trans-resveratrol UV photoisomerisation by means of HPLC–APCI-MS. J Photochem Photobiol A Chem 196(1):44–50. doi: 10.1016/j.jphotochem.2007.11.011 CrossRefGoogle Scholar
  32. Mudshinge SR, Deore AB, Patil S, Bhalgat CM (2011) Nanoparticles: emerging carriers for drug delivery. Saudi Pharm J SPJ Off Publ Saudi Pharm Soc 19(3):129–141. doi: 10.1016/j.jsps.2011.04.001 Google Scholar
  33. Neves AR, Lucio M, Lima JLC, Reis S (2012) Resveratrol in medicinal chemistry: a critical review of its pharmacokinetics, drug-delivery, and membrane interactions. Curr Med Chem 19(11):1663–1681. doi: 10.2174/092986712799945085 CrossRefGoogle Scholar
  34. Ng Y-J, Benson HAE, Brown DH, Chen Y (2015) Synthesis and characterization of novel copolymeric resveratrol conjugates. J Chem 2015:6. doi: 10.1155/2015/245625 CrossRefGoogle Scholar
  35. Nonomura S, Kanagawa H, Makimoto A (1963) Chemical Constituents of Polygonaceous Plants. I. Studies on the Components of Ko-J O-Kon. (Polygonum Cuspidatum Sieb. Et Zucc.). Yakugaku zasshi J Pharm Soc Japan 83:988–990CrossRefGoogle Scholar
  36. Pang X, Yang X, Zhai G (2014) Polymer-drug conjugates: recent progress on administration routes. Expert Opin Drug Deliv 11(7):1075–1086. doi: 10.1517/17425247.2014.912779 CrossRefGoogle Scholar
  37. Pangeni R, Sharma S, Mustafa G, Ali J, Baboota S (2014) Vitamin E loaded resveratrol nanoemulsion for brain targeting for the treatment of Parkinson’s disease by reducing oxidative stress. Nanotechnology 25(48):485102. doi: 10.1088/0957-4484/25/48/485102 CrossRefGoogle Scholar
  38. Park S et al (2016) Antibacterial nanocarriers of resveratrol with gold and silver nanoparticles. Mater Sci Eng, C 58:1160–1169. doi: 10.1016/j.msec.2015.09.068 CrossRefGoogle Scholar
  39. Penalva R, Esparza I, Larraneta E, González-Navarro CJ, Gamazo C, Irache JM (2015) Zein-based nanoparticles improve the oral bioavailability of resveratrol and its anti-inflammatory effects in a mouse model of endotoxic shock. J Agric Food Chem 63(23):5603–5611. doi: 10.1021/jf505694e CrossRefGoogle Scholar
  40. Rai G, Mishra S, Suman S, Shukla Y (2016) Resveratrol improves the anticancer effects of doxorubicin in vitro and in vivo models: a mechanistic insight. Phytomedicine 23(3):233–242. doi: 10.1016/j.phymed.2015.12.020 CrossRefGoogle Scholar
  41. Rege SD, Geetha T, Griffin GD, Broderick TL, Babu JR (2014) Neuroprotective effects of resveratrol in Alzheimer disease pathology. Front Aging Neurosci 6:218. doi: 10.3389/fnagi.2014.00218 CrossRefGoogle Scholar
  42. Renaud Sd, de Lorgeril M (1992) Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 339(8808):1523–1526. doi: 10.1016/0140-6736(92)91277-F CrossRefGoogle Scholar
  43. Saneja A, Dubey RD, Alam N, Khare V, Gupta PN (2014a) Co-formulation of P-glycoprotein substrate and inhibitor in nanocarriers: an emerging strategy for cancer chemotherapy. Curr Cancer Drug Targets 14(5):419–433. doi: 10.2174/1568009614666140407112034 CrossRefGoogle Scholar
  44. Saneja A, Khare V, Alam N, Dubey RD, Gupta PN (2014b) Advances in P-glycoprotein-based approaches for delivering anticancer drugs: pharmacokinetic perspective and clinical relevance. Expert Opin Drug Deliv 11(1):121–138. doi: 10.1517/17425247.2014.865014 CrossRefGoogle Scholar
  45. Sheu SY, Chen WS, Sun JS, Lin FH, Wu T (2013) Biological characterization of oxidized hyaluronic acid/resveratrol hydrogel for cartilage tissue engineering. J Biomed Mater Res A 101(12):3457–3466. doi: 10.1002/jbm.a.34653 CrossRefGoogle Scholar
  46. Siddalingappa B, Benson HA, Brown DH, Batty KT, Chen Y (2015) Stabilization of resveratrol in blood circulation by conjugation to mPEG and mPEG-PLA polymers: investigation of conjugate linker and polymer composition on stability, metabolism, antioxidant activity and pharmacokinetic profile. PLoS ONE 10(3):e0118824. doi: 10.1371/journal.pone.0118824 CrossRefGoogle Scholar
  47. Singh G, Pai RS (2014a) In-vitro/in vivo characterization of trans-resveratrol-loaded nanoparticulate drug delivery system for oral administration. J Pharm Pharmacol 66(8):1062–1076. doi: 10.1111/jphp.12232 Google Scholar
  48. Singh G, Pai RS (2014b) Optimized PLGA nanoparticle platform for orally dosed trans-resveratrol with enhanced bioavailability potential. Expert Opin Drug Deliv 11(5):647–659. doi: 10.1517/17425247.2014.890588 CrossRefGoogle Scholar
  49. Singh G, Pai RS (2014c) Recent advances of resveratrol in nanostructured based delivery systems and in the management of HIV/AIDS. J Control Release 194:178–188. doi: 10.1016/j.jconrel.2014.09.002 CrossRefGoogle Scholar
  50. Singh G, Pai RS (2015a) In vitro and in vivo performance of supersaturable self-nanoemulsifying system of trans-resveratrol. Artif cells Nanomed Biotechnol. doi: 10.3109/21691401.2014.966192 Google Scholar
  51. Singh G, Pai RS (2015b) Trans-resveratrol self-nano-emulsifying drug delivery system (SNEDDS) with enhanced bioavailability potential: optimization, pharmacokinetics and in situ single pass intestinal perfusion (SPIP) studies. Drug Deliv 22(4):522–530. doi: 10.3109/10717544.2014.885616 CrossRefGoogle Scholar
  52. Singh A, Ahmad I, Ahmad S, Iqbal Z, Ahmad FJ (2016) A novel monolithic controlled delivery system of resveratrol for enhanced hepatoprotection: nanoformulation development, pharmacokinetics and pharmacodynamics. Drug Dev Ind Pharm. doi: 10.3109/03639045.2016.1151032 Google Scholar
  53. Sirerol JA, Rodríguez ML, Mena S, Asensi MA, Estrela JM, Ortega AL (2015) Role of natural stilbenes in the prevention of cancer. Oxidative Med Cell longev. doi: 10.1155/2016/3128951 Google Scholar
  54. Solans C, Izquierdo P, Nolla J, Azemar N, Garcia-Celma M (2005) Nano-emulsions. Curr opinion in Colloid Interf Sci 10(3):102–110. doi: 10.1016/j.cocis.2005.06.004 CrossRefGoogle Scholar
  55. Soo E, Thakur S, Qu Z, Jambhrunkar S, Parekh HS, Popat A (2016) Enhancing delivery and cytotoxicity of resveratrol through a dual nanoencapsulation approach. J Colloid Interf Sci 462:368–374. doi: 10.1016/j.jcis.2015.10.022 CrossRefGoogle Scholar
  56. Summerlin N, Soo E, Thakur S, Qu Z, Jambhrunkar S, Popat A (2015) Resveratrol nanoformulations: challenges and opportunities. Int Journal Pharm 479(2):282–290. doi: 10.1016/j.ijpharm.2015.01.003 CrossRefGoogle Scholar
  57. Summerlin N et al (2016) Colloidal mesoporous silica nanoparticles enhance the biological activity of resveratrol. Colloids Surf B Biointerf 144:1–7. doi: 10.1016/j.colsurfb.2016.03.076 CrossRefGoogle Scholar
  58. Takaoka M (1940) Of the phenolic substances of white hellebore (Veratrum grandiflorum Loes. fil.). J Fac Sci Hokkaido Imp Univ 3:1–16Google Scholar
  59. Trela BC, Waterhouse AL (1996) Resveratrol: isomeric molar absorptivities and stability. J Agric Food Chem 44(5):1253–1257. doi: 10.1021/jf9504576 CrossRefGoogle Scholar
  60. Varoni EM, Faro AFL, Sharifi-Rad J, Iriti M (2016) Anticancer molecular mechanisms of resveratrol. Front Nutr. doi: 10.3389/fnut.2016.00008 Google Scholar
  61. Vian MA, Tomao V, Gallet S, Coulomb P, Lacombe J (2005) Simple and rapid method for cis-and trans-resveratrol and piceid isomers determination in wine by high-performance liquid chromatography using Chromolith columns. J Chromatogr A 1085(2):224–229. doi: 10.1016/j.chroma.2005.05.083 CrossRefGoogle Scholar
  62. Vijayakumar MR et al (2016) Intravenous administration of trans resveratrol loaded TPGS coated solid lipid nanoparticles for prolonged systemic circulation, passive brain targeting and improved in vitro cytotoxicity against C6 glioma cell lines. RSC Adv 6:50336–50348. doi: 10.1039/C6RA10777J CrossRefGoogle Scholar
  63. Walle T, Hsieh F, DeLegge MH, Oatis JE, Walle UK (2004) High absorption but very low bioavailability of oral resveratrol in humans. Drug Metabol Dispos 32(12):1377–1382. doi: 10.1124/dmd.104.000885 CrossRefGoogle Scholar
  64. Yang S et al (2015) Resveratrol elicits anti-colorectal cancer effect by activating miR-34c-KITLG in vitro and in vivo. BMC Cancer 15(1):1. doi: 10.1186/s12885-015-1958-6 CrossRefGoogle Scholar
  65. Yazgan ÜC, Taşdemir E, Bilgin HM, Deniz Obay B, Şermet A, Elbey B (2015) Comparison of the anti-diabetic effects of resveratrol, gliclazide and losartan in streptozotocin-induced experimental diabetes. Arch Physiol Biochem 121(4):157–161. doi: 10.3109/13813455.2015.1062898 CrossRefGoogle Scholar
  66. Zu Y et al (2014) Preparation and in vitro/in vivo evaluation of resveratrol-loaded carboxymethyl chitosan nanoparticles. Drug Delivery. doi: 10.3109/10717544.2014.924167 Google Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.Quality Control Quality Assurance and CMC DivisionCSIR-Indian Institute of Integrative MedicineJammuIndia
  2. 2.Academy of Scientific and Innovative Research (AcSIR)JammuIndia

Personalised recommendations